Manuel Salvisberg

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.